GEMOX or FOLFOX Promising Chemotherapeutic Options in Pulmonary Carcinoid Tumors

Share this content:
Gemcitabine-oxaliplatin or 5-fluourouracil-oxaliplatin combinations are promising chemotherapy regimens in metastatic pulmonary carcinoid tumors.
Gemcitabine-oxaliplatin or 5-fluourouracil-oxaliplatin combinations are promising chemotherapy regimens in metastatic pulmonary carcinoid tumors.

Gemcitabine-oxaliplatin or 5-fluourouracil-oxaliplatin combinations are promising chemotherapy regimens in metastatic pulmonary carcinoid tumors, according to a study published in Lung Cancer.1

In a retrospective study, investigators analyzed the efficacy of gemcitabine-oxaliplatin (GEMOX) or 5-fluorouracil-oxaliplatin (FOLFOX) in the treatment of metastatic pulmonary carcinoid tumors.

The study included 45 patients, whose carcinoids were classified as typical (19%), atypical (24%), or not otherwise specified (24%) according to the World Health Organization criteria. A total of 38% of patients had synchronous disease and 62% had metachronous metastatic disease. Seventy-nine patients had progressive disease prior to chemotherapy initiation.

Twenty-four patients received gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 every 2 weeks and 21 patients received 5-fluourouracil (400 mg/m2 in bolus injection) and 5-fluorouracil (2400 mg/m2 in a 46-hour infusion) as well as oxaliplatin 85 mg/m2 every 2 weeks.

Twenty percent of patients received first-line oxaliplatin-based treatment , 33% received it as second-line treatment, and 47% received it as post-second-line systemic therapy. The median number of cycles completed was 8.

In regard to safety, 20% of patients stopped treatment before 8 cycles due to treatment toxicity.

Results showed that 20% of patients had a partial response, 64% of patients had stable disease. Median progression-free survival was 15 months and median overall survival was 34 months.

RELATED: Negative Low-dose CT Prevalence Screening Linked With Lower Lung Cancer-specific Mortality

The authors noted that there was “no significant difference” observed in response and progression-free survival between the 2 regimens.

Reference

  1. Walter T, Planchard D, Bouledrak K, et al. Evaluation of the combination of oxaliplatin and 5-fluourouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors [article in press]. Lung Cancer. doi: 10.1016/j.lungcan.2016.03.018.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs